Cancer – SC-4007: A Phase 1 Study of the EZH2 Inhibitor Tazemtostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Condition or Therapy:
rhabdoid tumors, INI1-negative tumors, synovial sarcoma, malignant rhabdoid tumor of ovary, therapeutic drug tazmetostat
Cancer and Blood Disorders
Study Number: SC-4007
What is the goal of this study?
The goal of this study is to determine the maximum tolerated dose or the recommended phase 2 dose escalation and determine dose expansion in a number of subjects with objective response using disease-appropriate standardized response criteria.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are between 6 months to 18 years old, and
- Have a life expectancy of greater than three months, and
- Have been diagnosed with rhabdoid tumors, INI1-negative tumors, synovial sarcoma, or malignant rhabdoid tumor of ovary
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
For more information, call 206-987-2106 or email the study coordinator.